Close
Close

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Access Programs

Disease Information

Descriptive Information
Brief Title † A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Official Title † A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Onartuzumab (MetMAb) In Combination With 5-Fluorouracil, Folinic Acid, And Oxaliplatin (mFOLFOX6) In Patients With Metastatic Her2-Negative, Met-Positive Gastroesophageal Cancer (MetGastric)
Brief Summary This randomized, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with mFOLFOX6 in patients with metastatic HER2-negative and Met-positive adenocarcinoma of the stomach or gastroesophageal junction. Patients will be randomized in a 1:1 ratio to receive either onartuzumab (MetMAb) or placebo in combination with mFOLFOX6. Patients may continue to receive onartuzumab (MetMAb) or placebo until disease progression, unacceptable toxicity, patient or physician decision to discontinue treatment.
Detailed Description
Study Phase Phase 3
Study Type † Interventional
Study Design † Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary Outcome Measure † Overall survival (OS) in the Met IHC 2+/3+ patient subgroup
Secondary Outcome Measure † Progression-free survival
Condition † Gastric Cancer
Intervention † DrugOnartuzumab
Study Arms / Comparison Groups Onartuzumab Arm Placebo Arm
Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status † Drug
Estimated Enrollment † 564
Start Date † November 2012
Completion Date October 2015
Primary Completion Date October 2015
Eligibility Criteria † Inclusion Criteria: - Adult patients, 18 years of age and older - Adenocarcinoma of the stomach or gastroesophageal junction with inoperable, metastatic disease, not amenable for curative therapy - ECOG performance status 0 or 1 - Life expectancy >3 months - Presence of tissue sample for immunohistochemistry assay of Met receptor and HER2 status - Tumor (primary or metastatic lesion) defined as Met-positive by immunohistochemistry - Measurable disease or non-measurable but evaluable disease, according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1); Patients with peritoneal disease would generally be regarded as having evaluable disease and allowed to enter the trial. - For women who are not postmenopausal or surgically sterile; agreement to use an adequate method of contraception (e.g., hormonal implant) during the treatment period and for at least 90 days after the last dose of onartuzumab/placebo and 6 months after the last dose of oxaliplatin - For men: agreement to use a barrier method of contraception during the treatment period and for 90 days after the last dose of onartuzumab/placebo and 6 months after the last dose of oxaliplatin - Adequate laboratory values Exclusion Criteria: - HER2-positive tumor (primary tumor or metastasis) - Previous chemotherapy for locally advanced or metastatic gastric carcinoma (adjuvant or neoadjuvant chemotherapy must be completed at least 6 months prior to randomization) - Prior treatment with investigational drugs that target the HGF or Met pathway - History of another malignancy within the previous 5 years, except for appropriately treated and presumed cured carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer, and localized prostate cancer - Receipt of an investigational drug within 28 days prior to study start - Clinically significant gastrointestinal abnormalities, except from gastric cancer (e.g., Crohn's disease) - Significant history of cardiac disease - Significant vascular disease - Infection with human immunodeficiency virus, hepatitis B, or hepatitis C
Gender Both
Ages 18 Years - N/A
Accepts Healthy Volunteers No
Contacts ††
Location Countries † Australia
Administrative Information
NCT ID † NCT01662869
Organization ID YO28322
Secondary IDs †† 2012-001402-23
Responsible Party Sponsor
Study Sponsor † Hoffmann-La Roche
Collaborators †† Genentech, Inc.
Investigators † Study Director: Clinical Trials, Hoffmann-La Roche
Information Provided By
Verification Date October 2015
First Received Date † August 8, 2012
Last Updated Date October 1, 2015
† Required WHO trial registration data element.
†† WHO trial registration data element that is required only if it exists.
Find a Clinical Trial
Related Videos
Free Newsletter